Michael Cohen-Wolkowiez, MD, PhD
Kiser-Arena Distinguished Professor of Pediatrics
Professor of Pediatrics
Member in the Duke Clinical Research Institute
Campus mail:
300 West Morgan Street, Box 3850, Durham, NC 27701
Phone:
(919) 668-8812
Email address:
michael.cohenwolkowiez@duke.edu
Education and Training
- Pediatric Infectious Diseases Fellowship, Pediatrics, Duke University, 2006 - 2009
- Pediatric Chief Resident, Pediatrics, University of Miami, 2005 - 2006
- Pediatric Residency, Pediatrics, University of Miami, 2002 - 2005
- Ph.D., University of North Carolina at Chapel Hill School of Medicine, 2012
- M.D., Universidad Central de Venezuela (Venezuela), 2001
Selected Grants and Awards
- Real World Data to Support Pediatric Drug Labeling
- Mentoring in Clinical Pharmacology and Early Phase Trials
- Unified Program for Therapeutics in Children
- Duke CTSA (TL1)
- Duke Summer Training in Academic Research (Duke's STAR)
- Global Pediatric Clinical Trials Network
- Duke Resident Physician-Scientist Program- NIAID
- Pharmacokinetics, Pharmacodynamics, and Safety of Methylprednisolone in Neonates on Cardiopulmonary Bypass
- Duke Resident Physician-Scientist Program- NHLBI
- Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary Dysplasia
- Investigating polypharmacy-related adverse events in critically ill children using electronic health records and simulated drug levels
- RTOP 18-0006 Option 1 / Protocol Implementation
- TASK AREA A, TASK ORDER FY.2020.A1.0127 - Task Area A
- VTEU 13-0053 Task Area C
- Relationship between cerebrospinal fluid penetration of antimicrobials in infants and juvenile animals
- CIVICS Component C - Base to Option 6
- PTN2- TO#4 Data Closeout and Dissemination Option Period I
- Physiologically-Based Pharmacokinetic Modeling to Guide Drug Dosing in Children with Obesity
- Zika virus pathophysiology during pregnancy
- UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program
- Physiologically-Based Pharmacokinetic Models for Optimal Drug Dosing in Children
- Pediatric Trials Network_ Task Order 1_ Core Function Activities Option Period 1
- P1CTU_Task Order 16_Protocol Implementation (Mod 3)
- P1CTU_Task Order 16_Protocol Implementation
- VTEU Task Area D Option 9 Protocol FY.2016.D1.0026
- Parmacokinetic and pharmacogenomic approach to indomethacin therapy in pregnancy(Year 4,Amendment 3)
- RTOP 18-0006 Base / Protocol Development
- PTN TO #30 POPS Lab Mod. 2
- POPS Lab
- TASK AREA A, TASK ORDER FY.2019.A1.0118 - Task Area A
- PTN2- TO# Data Closeout and Dissemination
- PTN Task Order 25 SCAMP Modification
- PTN TO #25 SCAMP
- VTEU Task D Option 6 - FY.2017.B2C2D2.0053
- VTEU Task D Option 5 - FY.2017.B2C2D2.0053
- P1CTU Protocol Development for 17-0033 (Base)
- UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program
- VTEU Task Area D Option 9 Protocol FY.2016.D1.0026
- VTEU Task Area D Option 8B Protocol FY.2016.D1.0026
- Pediatric Trials Network_ Task Order 1_ Core Function Activities
- Echocardiogram to Diagnose Pulmonary Hypertension in Premature Infants
- PTN Task Order: CAFFEINE
- TASK AREA A, TASK ORDER FY.2018.A1.0095 Task Area A
- VTEU Task Area D Option 8 Protocol FY.2016.D1.0026
- SOLI - Solithromycin Pediatric Development Program (Phase 2/3)- Labor & Sub Cost
- Hyperimmune globulin treatment of Zika virus during pregnancy to reduce Congenital Zika Syndrome
- Duke CTSA (UL1)
- Pass-Through cost- CLIN04
- Role of pharmacokinetics and genomics in tocolytic therapy with indomethacin (subcontract)
- PTN POPS III
- P1CTU_Task Order 16_Protocol Development
- Phase I CTU Task Area A: Administrative and Overal Clinical Operations Support and Concept Development
- VTEU Task B - FY.2017.B2C2D2.0053
- PTN Task Order #17: Bioanalytical Analysis: POPS1, Fluconazole, and Meropenem
- SOLI - Solithromycin Pediatric Development Program (Phase 2/3 start up)- MOD 2
- TASK AREA A TASK ORDER FY.2016.A1.0041
- SOLI - Solithromycin Pediatric Development Program (Phase IB)- MOD 2
- Clinical Practice Data to Aid Narrow Therapeutic Index Drug Classification
- PTN Task Order #19: Lorazepam
- PTN Task Order 29: Clindamycin Bactrim
- CISA TO2 Prophylactic Antipyretics Revision 1-A
- CISA TO2 Prophylactic Antipyretics Revision 3-A
- CISA TO2 Prophylactic Antipyretics
- PTN Task Order #20: POPS II
- DAP Phase I PK/PD Analysis Budget
- The Pharmacokinetics of Extended Duration High-dose Cefixime Co-administered with Azithromycin for the Decreased Susceptibility of Neisseria gonorrhoeae: A Phase I Pilot Study
- The Pharmacokinetics of Extended Duration High-dose Cefixime Co-administered with Azithromycin for the Decreased Susceptibility of Neisseria gonorrhoeae: A Phase I Pilot Study
- Phase I CTU Task Area A: Administrative and Overal Clinical Operations Support and Concept Development
- Pharmacokinetics and Pharmacodynamics of Antibiotics in Premature Infants
- VTEU 13-0053 Task Area B
- PTN Task Order #3 - Safety and Pharmacokinetics of Multiple Dose Metronidazole in Premature Infants
- CTSA UL
- Best Pharmaceutical for Children Act (BPCA): Use of Meropenem in Infants